Nelly ZIADE 🍀 Nellziade
2 months ago
⏰ The question rheumatologists keep asking: Does early axSpA diagnosis reduce long-term spinal damage?
Answer from the SCQM registry (n=376): Early diagnosis linked to 3.85 fewer mSASSS points long-term, esp. in HLA-B27+ males
#POS0191 #EULAR2026 @RheumNow https://t.co/HM5kvqXMEh
Nelly ZIADE 🍀 Nellziade
2 months ago
📋 Do 2025 ASAS-SPARTAN criteria classify fewer real-world axSpA patients?
Data from the RABBIT-SpA registry (n=2,236) confirms:
67% vs 73% with 2009 criteria
Clinical arm rarely fulfilled
#POS0190 #EULAR2026 @RheumNow https://t.co/HYie4w8c6r
Dr. John Cush RheumNow
2 months ago
DAY 1 & 2 Recap: EULAR 2026 Highlights https://t.co/uVMerChWN6
Nelly ZIADE 🍀 Nellziade
2 months ago
☂️What is an umbrella meta-analysis?
It's a meta-analysis of meta-analyses ☔️
⬇️This one showed the effect of diet supplementation on several RA outcomes
Unfortunately, most studies have low levels of evidence
#umbrella #rainy_London #EULAR2026 @rheumnow https://t.co/kYPchXEexn
Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).
Nelly ZIADE 🍀 Nellziade
2 months ago
🔍 Are 2025 ASAS-SPARTAN criteria valid in early axSpA?
SPACE cohort (n=669):
HIGH specificity (97.5%) but LOWER sensitivity (60%) vs 2009 criteria (83%)
#OP0239 #EULAR2026 @RheumNow https://t.co/9wNbtcbP0l
Dr. John Cush RheumNow
2 months ago
A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology
EULAR launches a Study Group on Geriatric Rheumatology — clinics increasingly serve older patients with multimorbidity, polypharmacy, frailty, cognitive and functional limits, yet research
Bella Mehta bella_mehta
2 months ago
Window of opportunity in stills disease is early. With IL1 / IL6 agents
#sJIA and #AOSD are the same disease. - may need a standard new crieteria
IL18 measuremnet should be encouraged.
@RheumNow #EULAR2026 plenary https://t.co/EQbs9mDYjS
Bella Mehta bella_mehta
2 months ago
Transitioning from pediatrics to adult rheumatology for patients with autoinflammatory disease such as #AOSD should be done with administrative support and the right hand off.
@RheumNow #EULAR2026 plenary talk https://t.co/N8qB7jrZfM
Nelly ZIADE 🍀 Nellziade
2 months ago
🔬 Can filgotinib improve axSpA?
OLINGUITO (Phase 3 RCT, n=495):
YES! ASAS40 39.5% vs 21% (r-axSpA) at week 16
#OP0234 #EULAR2026 @RheumNow https://t.co/0vj2KqSS1b
Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs. EULAR has recommendations that cover glucocorticoid use in ANCA associated vasculitides (AAV) and large vessel vasculitis, including giant cell arteritis (GCA).1,2 But the evidence base continues to grow about their use – especially over the long term.
sheila RHEUMarampa
2 months ago
What defines MRI indicative of axSpA?
This systematic lit review show adapting more stringent cutoffs in BME (>=4 SIJ quads, erosion >=3 quads, fat >=5 SIJ quads) & combined BME + structural lesions inc specificity.
Time for updated definitions?
AbsPOS0866 @RheumNow #EULAR2026 https://t.co/gkVbcOAiD3
Nelly ZIADE 🍀 Nellziade
2 months ago
@RheumNow WIN Nutrition session #EULAR2026 (4)
🌾 Gluten does NOT influence biologic response in RD, BELIEVE cohort, 197 pts. No need to go gluten-free unless celiac disease
🌱 Plants for Joints trial: plant-based diet + exercise → sustained DAS28&WOMAC improvement @ 2Y, RA/OA
@RheumNow
Nelly ZIADE 🍀 Nellziade
2 months ago
@RheumNow WIN Nutrition session at #EULAR2026 (3)
6.🍟 High UPF intake → increased RA risk (HR 1.06/SD), partly mediated by CRP. Not all NOVA-4 foods are equal
7.💊 Vit D supplementation significantly reduces SLE disease activity — MA of 10 RCTs, SMD −0.54 (p<0.00001).
@RheumNow
